Transrectal Ultrasound Market Outlook:
Transrectal Ultrasound Market size was USD 271.5 million in 2025 and is projected to reach USD 494.9 million by the end of 2035, increasing at a CAGR of 6.9% during the forecast period, i.e., 2026-2035. In 2026, the industry size of transrectal ultrasound is assessed at USD 290.2 million.
The market is witnessing significant growth, which is propelled by a surge in cancer cases, technological innovation optimizing diagnostic accuracy, increased awareness and early screening emphasis, healthcare infrastructure expansion, and suitable reimbursement policies. According to a report published by the National Cancer Institute in 2025, the estimated latest prostate cancer cases as of 2025 are 313,780, accounting for 15.4% of all cancer cases. In addition, approximate deaths, owing to this condition, are 35,770 within the same year range, accounting for 5.8% of overall cancer deaths. Therefore, with this high prevalence, there is a huge opportunity for the market to flourish internationally.
Source: UNCTAD, 2025
Moreover, there has been a rapid expansion in frontier technologies, such as artificial intelligence (AI), the Internet of Things (IoT), nanotechnology, gene editing, blockchain, 3D printing, and robotics, which are driving the market demand. As per the 2025 UNCTAD report, these technologies displayed a USD 2.5 trillion valuation, as of 2023, which is projected to increase to USD 16.4 trillion by the end of 2033. Additionally, AI is estimated to garner the majority of its share of approximately USD 4.8 trillion, which is 30% of the frontier technology market by 2033. Meanwhile, the IoT will also contribute USD 3.1 trillion within the same year, while large-scale companies are responsible for market capitalization, thus suitable for boosting the overall market.

Transrectal Ultrasound Market - Growth Drivers and Challenges
Growth Drivers
- Early screening technologies: These are essential, owing to their usefulness in detecting diseases, enhancing the likelihood of successful treatment, ensuring a surge in survival rates, and preventing the condition from appearing to be life-threatening. As per an article published by NLM in June 2025, the low-dose computed tomography (LDCT) has the capability to reduce lung cancer-based mortality by 20% to 24% in two essential clinical trials, including the Dutch-Belgian Lung Cancer Screening Trial and the public National Lung Screening Trial (NLST), thus creating an optimistic opportunity for the transrectal ultrasound market’s exposure.
- Novel therapeutic applications: These applications provide solutions for untreated disorders, ensure personalized treatments, optimize efficiency and safety, and enhance patients’ quality, thereby uplifting the market globally. As per the August 2024 NLM article, the immune checkpoint inhibitors integration resulted in a 3-year survival rate of 22%, based on a pooled meta-analysis of 10 prospective and 2 retrospective trials for 1,861 advanced melanoma patients. Therefore, the existence of such therapeutic applications, there is a huge scope for the market’s upliftment across different nations.
- Robotic surgery integration: This particular surgery permits huge precision and control, especially during complicated surgical procedures, resulting in enhanced patient outcomes, which is responsible for the market’s upliftment. As stated in the June 2025 NLM article, AI-based robotic surgeries constitute the capability to reduce operative duration by 25%, resulting in a 30% decrease in intraoperative complications. In addition, there have been improvements in surgical precision by 40%, a diminish in patient recovery times by 15%, thus contributing to the market’s development.
Prostate Cancer Driving the Transrectal Ultrasound Market
2020-2023 Prostate Cancer Cases, Deaths, and Survival
Year |
Rate of New Cases- SEER 8 |
Rate of New Cases- SEER 12 |
Death Rate- U.S. |
5-Year Relative Survival- SEER 8 |
||||
Observed |
Modeled Trend |
Observed |
Modeled Trend |
Observed |
Modeled Trend |
Observed |
Modeled Trend |
|
2020 |
109.08 |
124.16 |
103.10 |
117.56 |
19.59 |
19.30 |
- |
98.74% |
2021 |
129.47 |
127.84 |
122.88 |
121.04 |
19.15 |
19.19 |
- |
98.91% |
2022 |
126.75 |
131.63 |
120.36 |
124.62 |
19.07 |
19.08 |
- |
99.05% |
2023 |
- |
- |
- |
- |
18.71 |
18.97 |
- |
- |
Source: National Cancer Institute, 2025
Research and Development (R&D) Uplifting the Market Globally
2012-2022 Significant R&D Concentration in a Few Countries
Country Name |
2012 |
2022 |
U.S. |
39% |
49% |
China |
2% |
13% |
Germany |
11% |
12% |
Japan |
20% |
8% |
Republic of Korea |
4% |
4% |
Switzerland |
4% |
6% |
UK |
3% |
3% |
Source: UNCTAD, 2025
Challenges
- Strict HTA and cost-effectiveness obstacles: The aspect gaining market accessibility demands evidence from government-based HTA bodies regarding the latest TRUS technology to provide suitable value, which has created a gap in the market growth. This ensures lengthy and expensive real-world clinical studies to demonstrate accuracy in diagnosis, as well as downstream clinical advantages. Besides, a poor HTA evaluation can obstruct reimbursement services, confine technology to private markets, and limit patient reach, thereby hampering the market’s exposure.
- Barriers in reference and government pricing: The presence of national health systems in Asia and Europe has strictly employed external reference pricing, determining the new device expense based on the lowest price. This strategy effectively crushed profit margins and eliminated flexibility among manufacturers, thereby causing a hindrance in the market internationally. In addition, organizations are unable to provide discounts across lower-income nations without the risk of a devastating price cut, particularly in Europe-based markets.
Transrectal Ultrasound Market Size and Forecast:
Report Attribute | Details |
---|---|
Base Year |
2025 |
Forecast Year |
2026-2035 |
CAGR |
6.9% |
Base Year Market Size (2025) |
USD 271.5 million |
Forecast Year Market Size (2035) |
USD 494.9 million |
Regional Scope |
|
Transrectal Ultrasound Market Segmentation:
End user Segment Analysis
The hospitals segment in the market is anticipated to garner the highest share of 65.8% by the end of 2035. The segment’s upliftment is propelled by emerging as the primary center for conducting complicated diagnostic and surgical processes. Hospitals possess the required capital to invest in MRI-TRUS fusion platforms and high-end cart-based TRUS systems, which are usually expensive than small-scale clinical facilities. Besides, these infrastructures effectively adopt multidisciplinary teams, including radiologists, urologists, oncologists, and specialized nursing staff to carefully interpret and perform standard biopsies, thus suitable for the segment’s growth.
Portability Segment Analysis
The cart-based systems segment in the transrectal ultrasonic market is expected to account for the second-highest share of 60.3% during the forecast period. The segment’s growth is effectively fueled by its ability to optimize efficiency, provide necessary equipment for patients, and improve patient safety. Regarding this, a clinical study was published by NLM in February 2024, wherein 110 patients were enrolled. Additionally, 56 patients constituted the cart-based model, and 54 for handheld devices. The result demonstrated 90% diagnostic accuracy for the cart-based model, in comparison to 70% for handheld devices, thus suitable for the segment’s growth.
Application Segment Analysis
Based on the application, the biopsy guidance segment in the market is projected to hold the third-highest share of 55.3% by the end of the forecast timeline. The segment’s growth is highly driven by its capability to ensure accurate diagnosis, enable precision in identifying diseases, and provide detailed information. In this regard, a clinical study was published by NLM in October 2023, wherein CT-guided core biopsy was evaluated on 447 patients. The outcome displayed that 85% was the success rate for 275 females and 314% for 172 males, thus denoting a positive impact for the segment.
Our in-depth analysis of the global market includes the following segments:
Segment |
Subsegments |
End user |
|
Product Type |
|
Application |
|
Component |
|
Image Guidance Technology |
|
Probe Type |
|

Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Transrectal Ultrasound Market - Regional Analysis
North America Market Insights
North America transrectal ultrasound market is projected to emerge as the dominating region by garnering the largest share of 35.8% by the end of 2035. The market’s upliftment in the region is highly propelled by an increase in innovative technology, a suitable reimbursement landscape, a surge in cancer screening awareness, and robust healthcare facilities. According to the January 2025 American Hospital Association report, there are 6,093 hospitals in the U.S., of which 5,112 cater to community hospitals. In addition, there are a total of 913,136 staffed beds, along with 34,426,650 hospital admissions, which is positively impacting the market.
The transrectal ultrasound market in the U.S. is significantly growing, owing to technological and clinical integration, reimbursement and regulatory policies, the presence of industrial and economic leaders, and awareness regarding cancer cases. As per the April 2022 CDC report, cancer is the second leading reason of death, just after heart disease, in the country, with 1,708,921 people newly diagnosed and 599,265 deaths. Besides, there has been a reduction in screening, catering to 21.6% over the past 5 years, and 69.4% adults were detected with colorectal cancer. Therefore, a surge in the disease denotes a huge growth opportunity for the market in the country.
The transrectal ultrasound market in Canada is also growing due to governmental and structural investments, universal coverage accessibility, logistical and geographic-specific care, and effective focus on public health. According to the data report published by the Government of Canada in November 2024, there have been an estimated 220,400 new cancer cases in the country, for which USD 159 million was provided to conduct thorough research. Besides, the Integrated Strategy for Healthy Living and Chronic Disease initiated a USD 300 million fund to ensure federal leadership throughout the country. Meanwhile, the aspect of healthcare expenditure is also bolstering the market across the overall region.
Public Healthcare Expenditure in North America
Countries |
Expenditure (GDP %) |
Cuba |
12.6 |
U.S. |
9.6 |
Canada |
8.0 |
Costa Rica |
5.3 |
Jamaica |
5.1 |
Dominica |
4.2 |
Bahamas |
4.0 |
Mexico |
3.0 |
Source: PAHO, October 2024
APAC Market Insights
Asia Pacific in the transrectal ultrasound market is anticipated to emerge as the fastest-growing region, accounting for a share of 25.4% by the end of the forecast period. The market’s development in the region is highly attributed to its extreme economic and demographic diversity, overwhelming demographic shift, a huge expansion in governmental healthcare, modernized initiatives, and a growth in the medical tourism sector. According to an article published by NLM in May 2024, the region approximately caters to 25% of the global population and is a home to more than 4,500 defined groups. Therefore, with the presence of a huge population, the market constitutes an opportunity to grow in the overall region.
The transrectal ultrasound market in China is gaining increased exposure, owing to the Health China 2030 initiative, technological dominance, and a surge in the chronic disease burden. According to the December 2023 NLM article, non-communicable diseases account for 88.5% of overall deaths and 84.9% of the disease burden in the country. Besides, there has been a rise in age-standardized rates for cancer prevalence and incidence by 135.2% and 27.9%, which is surging the market’s demand. Therefore, with an increase in the occurrence of chronic diseases in the country, there is a huge opportunity for the market’s upliftment.
The transrectal ultrasound market in India is gradually developing due to an increase in private hospital accessibility, governmental healthcare policies, and the teleradiology implementation. As stated in the April 2023 NLM article, 60% of the country’s population resides in rural regions, wherein there is difficulty in healthcare access, while for a 1.4 billion population, the number of radiologists is quite less. Therefore, teleradiology has been one of the most standard solutions to provide remote healthcare to patients. Meanwhile, the availability of ultrasonic medical scanners is also suitable for boosting the overall market in the region.
Ultrasonic Medical Scanners 2023 Export and Import in Asia
Countries |
Export |
Import |
China |
USD 106 million |
USD 22.5 million |
Japan |
- |
USD 20.4 million |
India |
USD 65.2 million |
USD 2.9 million |
Indonesia |
USD 11.1 million |
- |
United Arab Emirates |
USD 9.6 million |
- |
Philippines |
USD 8.9 million |
- |
Singapore |
- |
USD 4.2 million |
Source: OEC
Europe Market Insights
Europe in the transrectal ultrasound market is expected to account for a considerable share of 28.6% during the projected timeline. The market’s growth in the region is effectively driven by cross-border strategies, supranational policy, Medical Device Regulation (MDR) implementation, and pan-European research funding through Horizon Europe. Based on this, the 2020 federal government strategy has focused on research and innovation promotion in health, strengthening health systems, along with addressing health issues and cross-border challenges, thus suitable for the market’s upliftment.
The transrectal ultrasound market in Germany is steadily growing, owing to regulatory and reimbursement policies, structural clinical care facilities, and standard clinical practices. As stated in the August 2025 ITA report, the healthcare industry in the country has effectively employed 6.1 million people and ranks among the top ten countries globally in healthcare expenditure. In addition, the medical device market in the country also has a huge exposure, accounting for almost USD 44 billion in revenue every year, which makes up to 26.5% of the overall Europe region, thereby denoting an optimistic outlook for the market.
The transrectal ultrasound market in France is also growing due to the existence of governmental health strategies, financial and reimbursement services, and a strong healthcare infrastructure. According to the 2023 Diplomatie Government report, the country successfully undertook the responsibility of training healthcare professionals, of which 70% are women. Besides, over €10 billion has been invested by the country, as a global fund, to overcome AIDS, malaria, and tuberculosis, denoting a huge contribution, which in turn, is suitable for the market’s growth.

Key Transrectal Ultrasound Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global market is effectively consolidated and severely dominated by key players, including GE Healthcare, Philips, and Siemens Healthineers, jointly competing on technological superiority AI implementation, improved imaging algorithms, and seamless MRI fusion capabilities. Their notable strategy is to lock massive hospital facilities with premium and ecosystem-specific solutions, which denotes a huge growth opportunity for the overall market internationally. Meanwhile, firms in China, such as Chison and Mindray, readily pursued aggressive growth through targeted price-sensitive markets, cost leadership, and mid-tier clinics with value-oriented and reliable systems.
Here is a list of key players operating in the global market:
Company Name (Country of Origin) |
Industry Focus & Notable Products |
Estimated 2025 Market Share |
Siemens Healthineers (Germany) |
A global leader in medical imaging. Offers high-end, AI-powered biplane and multi-plane TRUS systems, often integrated with MRI for fusion-guided biopsies. |
23.2% |
Philips (Netherlands) |
Provides advanced ultrasound platforms with specialized TRUS transducers and integrated solutions for urology, including real-time fusion biopsy technology. |
20.8% |
GE HealthCare (U.S.) |
Develops comprehensive ultrasound systems with dedicated urology imaging capabilities, focusing on clarity and workflow efficiency for prostate diagnostics. |
18.2% |
Samsung Medison (South Korea) |
A major player in medical ultrasound. Offers a range of systems that include specialized curvilinear transducers for prostate imaging. |
9.4% |
Mindray (China) |
A leading global medical device supplier. Provides cost-effective and high-performance ultrasound systems with TRUS capabilities for a broad market. |
8.7% |
BK Medical (Denmark) |
(Acquired by Analogic) A specialist in advanced surgical ultrasound and urological imaging, known for high-performance systems designed for precise interventions. |
xx% |
Esaote S.p.A. (Italy) |
Specializes in medical imaging, particularly MRI and ultrasound, with systems designed for specialized applications including urology. |
xx% |
FUJIFILM SonoSite, Inc. (U.S.) |
Known for point-of-care ultrasound, its higher-end systems offer capabilities suitable for urological procedures and diagnostics. |
xx% |
Chison Medical Technologies (China) |
A growing manufacturer offering a wide range of diagnostic ultrasound equipment, including models with TRUS functionality, at competitive prices. |
xx% |
Hologic, Inc. (U.S.) |
While focused on women's health, its imaging division develops advanced ultrasound technologies with applications across various specialties. |
xx% |
Medtronic plc (Ireland) |
While primarily a device-therapy company, its surgical navigation and visualization technologies can integrate with imaging systems for urological procedures. |
xx% |
Carestream Health (U.S.) |
Provides medical imaging systems, including digital radiography and ultrasound, with solutions applicable for general and specialized diagnostics. |
xx% |
Contextvision (Sweden) |
Provides advanced image analysis and AI-based software that is often integrated into other manufacturers' ultrasound systems to enhance image quality for diagnostics. |
xx% |
Telemed Medical Systems (Lithuania) |
Develops ultrasound systems and specialized software solutions, with a focus on accessibility and telehealth applications. |
xx% |
Meda Co., Ltd (South Korea) |
A manufacturer of diagnostic ultrasound systems, offering a range of products that compete in the value segment of the global market. |
xx% |
Below are the areas covered for each company in the market:
Recent Developments
- In May 2025, Astellas Pharma Inc., along with Pfizer Inc. declared the extension of the Phase III ARCHES, denoting a five-year follow up and 30% reduction in death risk among men with metastatic hormone-sensitive prostate cancer (mHSPC) aided with XTANDI.
- In April 2024, Best Nomos, which is a part of TeamBest Global Companies, launched the highly advanced Compact SONALIS Ultrasound System, comprising modern, flexible, and novel system to provide the highest resolution.
- Report ID: 8058
- Published Date: Sep 05, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Frequently Asked Questions (FAQ)
Transrectal Ultrasound Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert